-
Mashup Score: 0Intravenous iron in patients with heart failure and iron deficiency: an updated meta-analysis - PubMed - 1 month(s) ago
In patients with HF and ID, this meta-analysis suggests that IV iron reduces the risk of HHF but whether this is associated with a reduction in cardiovascular or all-cause mortality remains inconclusive.
Source: pubmed.ncbi.nlm.nih.govCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 3Frailty and survival among veterans treated with abiraterone or enzalutamide for metastatic castration-resistant prostate cancer - 2 month(s) ago
Abiraterone and enzalutamide are treatments for metastatic castration-resistant prostate cancer (mCRPC). Due to a lack of head-to-head trials, they are prescribed interchangeably. However, the drugs have different pharmacokinetics and thus may have differing efficacy and adverse effects influenced by patient functional status and comorbid diseases. Additionally, mCRPC mainly affects older adults and since the prevalence of frailty increases with age, frailty is an important patient factor to consider in personalizing drug selection.
Source: www.geriatriconcology.netCategories: General Medicine News, Hem/OncsTweet-
@AaronGoodman33 Shameless plug, retrospective studies of old and frail patients should compare similar treatments, while not as good as randomized prospective, they may provide the best data available since some prospective trials are not feasible https://t.co/LXT4wG6Kwd
-
-
Mashup Score: 31Survival in Patients With De Novo Metastatic Prostate Cancer - 10 month(s) ago
This cross-sectional study investigates trends in overall survival among patients with newly diagnosed metastatic prostate cancer in 2 national registries in the United States.
Source: jamanetwork.comCategories: General Medicine News, Hem/OncsTweet-
Survival in metastatic prostate cancer is improving in the general US population over the last 20 years based on data from SEER and @DeptVetAffairs. The improvement is mainly in patients <70 years old, who are likely similar to patients in clinical trials https://t.co/u3oCfQw55d https://t.co/puMc0RvdnO
-
-
Mashup Score: 4
Background Abiraterone acetate and enzalutamide are two common therapies for metastatic castration-resistant prostate cancer (mCRPC) that have shown improved overall survival (OS). The drugs have di…
Source: onlinelibrary.wiley.comCategories: General Medicine News, Hem/OncsTweet-
Thanks to @DeptVetAffairs @VAResearch @SLU_Official as well as @CDMRP and @PCFnews @PCF_Science for supporting this work. https://t.co/Txh8MZfz9v
-
-
Mashup Score: 0Risk of Recurrence After Radiation in Early Prostate Cancer—Role of Risk Stratification From Prospective Trials - 1 year(s) ago
The role of adjuvant therapy in any malignant neoplasm is to reduce the rate of relapse and, in some patients, increase the chance of cure. Over the last decade, several studies of patients with localized prostate cancer had reported decreased risk of biochemical recurrence or metastasis with…
Source: jamanetwork.comCategories: Hem/Oncs, Latest HeadlinesTweet-
Great to see data from trials used for multiple purposes. Wrote a small commentary on a retrospective trial analysis by @MutlaySayan and Anthony D'Amico. PSA, Gleason, and age further risk stratify risk of PSA recurrence @PCF_Science @slu_ahead https://t.co/XguietDaS4
-
-
Mashup Score: 0Mortality in the US Populations With MGUS - 1 year(s) ago
This cohort study analyzes a nationally representative sample with a screening test for monoclonal gammopathy of undetermined significance (MGUS) to evaluate overall survival of populations with MGUS compared with those without MGUS among the general population in the US.
Source: jamanetwork.comCategories: Hem/Oncs, Latest HeadlinesTweet-
RT @gcolditz: Mortality in the US Populations With MGUS https://t.co/zqBWce702U Updated national data - great to be part of this team effo…
-
-
Mashup Score: 0Program Guide – ASCO Meeting Program Guide - 2 year(s) ago
AuthorsMartin W. SchoenSaint Louis University School of Medicine, St. Louis, MOMartin W. Schoen, Lukas Owens, Suhong Luo, Robert Bruce Montgomery, Kristen Marie Sanfilippo, Ruth Douglas EtzioniOrganizationsSaint Louis University School of Medicine, St. Louis, MO, Fred Hutchinson Cancer Research Center, Seattle, WA, Washington University in St. Louis, St. Louis, MO, University of Washington,…
Source: meetings.asco.orgCategories: Hem/Oncs, Latest HeadlinesTweet-
@dr_coops @VeteransHealth @etzionime Thanks for noticing! Survival is improving and we are using more doublet therapy For more information: https://t.co/za39iD9DPv @SLUHealthNews @DeptVetAffairs @VREFSTL https://t.co/mNo8hvxhih @KSanfilippoMD
-
-
Mashup Score: 1Survival Improving in De Novo mHSPC Cases - 2 year(s) ago
In the VHA system, use of doublet therapy increased to more than 50% of mHSPC cases since 2020.
Source: Renal and Urology NewsCategories: Hem/Oncs, Latest HeadlinesTweet-
Survival Improving in De Novo metastatic hormone sensitive prostate cancer, more in younger men. Doublet therapy increasing in the VA. Since 2020, >50% receive doublet for mHSPC @PCF_Science @PCFnews @KSanfilippoMD @DeptVetAffairs https://t.co/mNo8hvxhih
-
-
Mashup Score: 0Treatment of Mantle-Cell Lymphoma | NEJM - 2 year(s) ago
Correspondence from The New England Journal of Medicine — Treatment of Mantle-Cell Lymphoma
Source: New England Journal of MedicineCategories: Hem/Oncs, Latest HeadlinesTweet-
SHINE authors: 'median overall survival now numerically favors the ibrutinib group over the placebo group (100.6 months vs. 94.2 months), and the hazard ratio for death is 1.00 (95% confidence interval, 0.77 to 1.30)' Really? 'numerically favors'? What? https://t.co/Hj8Sjseh7G
-
-
Mashup Score: 1Survival of veterans treated with enzalutamide and abiraterone for metastatic castrate resistant prostate cancer based on comorbid diseases - 2 year(s) ago
Comorbid diseases influence patient outcomes, yet little is known about how comorbidities interact with treatments for metastatic castrate-resistant prostate cancer (mCRPC). No head-to-head trials have compared the efficacy of abiraterone and enzalutamide – oral androgen-receptor targeted agents (ARTAs) for mCRPC. In patients with comorbid disease, outcomes with ARTAs may differ due to disparate…
Source: www.nature.comCategories: Hem/Oncs, Latest HeadlinesTweet-
My latest #research that shows improved survival with enzalutamide over abiraterone in mCRPC, especially in patients with cardiac disease or diabetes https://t.co/eOLckfIPkH, published with @SpringerNature in @pcan_journal with support of @DeptVetAffairs @PCFnews @KSanfilippoMD
-
@ProfMakris @KSanfilippoMD @BrJHaem I am not so sure that MRI imaging of the heart is the ideal outcome. There is a body of evidence that IV iron may be beneficial or safe based on clinical outcomes in high risk patients https://t.co/WJEdYJRVaC @Bloodman @barttels2